|
1
|
Ljungberg B, Campbell SC, Choi HY, Jacqmin
D, Lee JE, Weikert S and Kiemeney LA: The epidemiology of renal
cell carcinoma. Eur Urol. 60:615–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Znaor A, Lortet-Tieulent J, Laversanne M,
Jemal A and Bray F: International variations and trends in renal
cell carcinoma incidence and mortality. Eur Urol. 67:519–530. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eikrem OS, Strauss P, Beisland C, Scherer
A, Landolt L, Flatberg A, Leh S, Beisvag V, Skogstrand T, Hjelle K,
et al: Development and confirmation of potential gene classifiers
of human clear cell renal cell carcinoma using next-generation RNA
sequencing. Scand J Urol. 50:452–462. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jonasch E, Gao J and Rathmell WK: Renal
cell carcinoma. BMJ. 349:g47972014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou L, Yin B, Liu Y, Hong Y, Zhang C and
Fan J: Mechanism and function of decreased FOXO1 in renal cell
carcinoma. J Surg Oncol. 105:841–847. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ficarra V and Novara G: Kidney cancer:
Characterizing late recurrence of renal cell carcinoma. Nat Rev
Urol. 10:687–689. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ricketts CJ, De Cubas AA, Fan H, Smith CC,
Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, et al:
The cancer genome atlas comprehensive molecular characterization of
renal cell carcinoma. Cell Rep. 23:36982018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barrett T, Troup DB, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, et al: NCBI GEO: Archive for functional genomics data
sets-10 years on. Nucleic Acids Res. 39:Database Issue.
D1005–D1010. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Edge SB, Byrd DR and Compton CC: AJCC
cancer staging manual. 7th. Springer-Verlag; New York: pp. 547–560.
2009
|
|
14
|
Eckel-Passow JE, Serie DJ, Bot BM, Joseph
RW, Cheville JC and Parker AS: ANKS1B is a smoking-related
molecular alteration in clear cell renal cell carcinoma. BMC Urol.
14:142014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peña-Llopis S, Vega-Rubin-de-Celis S, Liao
A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L,
Sivanand S, Spence P, et al: BAP1 loss defines a new class of renal
cell carcinoma. Nat Genet. 44:751–759. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gerlinger M, Horswell S, Larkin J, Rowan
AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos
CR, et al: Genomic architecture and evolution of clear cell renal
cell carcinomas defined by multiregion sequencing. Nat Genet.
46:225–233. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
von Roemeling CA, Radisky DC, Marlow LA,
Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW and Copland JA:
Neuronal pentraxin 2 supports clear cell renal cell carcinoma by
activating the AMPA-selective glutamate receptor-4. Cancer Res.
74:4796–4810. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kolde R, Laur S, Adler P and Vilo J:
Robust rank aggregation for gene list integration and
meta-analysis. Bioinformatics. 28:573–580. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vosa U, Kolde R, Vilo J, Metspalu A and
Annilo T: Comprehensive meta-analysis of microRNA expression using
a robust rank aggregation approach. Methods Mol Biol. 1182:361–373.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang X, Zhu S, Li L, Zhang L, Xian S, Wang
Y and Cheng Y: Identification of differentially expressed genes and
signaling pathways in ovarian cancer by integrated bioinformatics
analysis. Onco Targets Ther. 11:1457–1474. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen JS, Hung WS, Chan HH, Tsai SJ and Sun
HS: In silico identification of oncogenic potential of fyn-related
kinase in hepatocellular carcinoma. Bioinformatics. 29:420–427.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Metz CE: Basic principles of ROC analysis.
Semin Nucl Med. 8:283–298. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mootha VK, Lindgren CM, Eriksson KF,
Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E,
Ridderstråle M, Laurila E, et al: PGC-1alpha-responsive genes
involved in oxidative phosphorylation are coordinately
downregulated in human diabetes. Nat Genet. 34:267–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takata M, Yamanaka N, Tanaka T, Yamanaka
J, Maeda S, Okamoto E, Yasojima H, Uematsu K, Watanabe H and
Uragari Y: What patients can survive disease free after complete
resection for hepatocellular carcinoma? A multivariate analysis.
Jpn J Clin Oncol. 30:75–81. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Girgis H, Masui O, White NM, Scorilas A,
Rotondo F, Seivwright A, Gabril M, Filter ER, Girgis AH, Bjarnason
GA, et al: Lactate dehydrogenase A is a potential prognostic marker
in clear cell renal cell carcinoma. Mol Cancer. 13:1012014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
King SC, Pollack LA, Li J, King JB and
Master VA: Continued increase in incidence of renal cell carcinoma,
especially in young patients and high grade disease: United States
2001 to 2010. J Urol. 191:1665–1670. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Levi F, Ferlay J, Galeone C, Lucchini F,
Negri E, Boyle P and La Vecchia C: The changing pattern of kidney
cancer incidence and mortality in Europe. BJU Int. 101:949–958.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jeffery J, Sinha D, Srihari S, Kalimutho M
and Khanna KK: Beyond cytokinesis: The emerging roles of CEP55 in
tumorigenesis. Oncogene. 35:683–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao WM, Seki A and Fang G: Cep55, a
microtubule-bundling protein, associates with centralspindlin to
control the midbody integrity and cell abscission during
cytokinesis. Mol Biol Cell. 17:3881–3896. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fabbro M, Zhou BB, Takahashi M, Sarcevic
B, Lal P, Graham ME, Gabrielli BG, Robinson PJ, Nigg EA, Ono Y and
Khanna KK: Cdk1/Erk2- and Plk1-dependent phosphorylation of a
centrosome protein, Cep55, is required for its recruitment to
midbody and cytokinesis. Dev Cell. 9:477–488. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jeffery J, Neyt C, Moore W, Paterson S,
Bower NI, Chenevix-Trench G, Verkade H, Hogan BM and Khanna KK:
Cep55 regulates embryonic growth and development by promoting Akt
stability in zebrafish. FASEB J. 29:1999–2009. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu ZY, Ma XS, Qi ST, Wang ZB, Guo L,
Schatten H, Sun QY and Sun YP: Cep55 regulates spindle organization
and cell cycle progression in meiotic oocyte. Sci Rep. 5:169782015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen CH, Lu PJ, Chen YC, Fu SL, Wu KJ,
Tsou AP, Lee YC, Lin TC, Hsu SL, Lin WJ, et al: FLJ10540-elicited
cell transformation is through the activation of PI3-kinase/AKT
pathway. Oncogene. 26:4272–4283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li M, Gao J, Li D and Yin Y: CEP55
promotes cell motility via JAK2-STAT3-MMPs cascade in
hepatocellular carcinoma. Cells. 7(pii): E992018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang YF, Zhang MF, Tian QH, Fu J, Yang X,
Zhang CZ and Yang H: SPAG5 interacts with CEP55 and exerts
oncogenic activities via PI3K/AKT pathway in hepatocellular
carcinoma. Mol Cancer. 17:1172018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sakai M, Shimokawa T, Kobayashi T,
Matsushima S, Yamada Y, Nakamura Y and Furukawa Y: Elevated
expression of C10orf3 (chromosome 10 open reading frame 3) is
involved in the growth of human colon tumor. Oncogene. 25:480–486.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Inoda S, Hirohashi Y, Torigoe T,
Nakatsugawa M, Kiriyama K, Nakazawa E, Harada K, Takasu H, Tamura
Y, Kamiguchi K, et al: Cep55/c10orf3, a tumor antigen derived from
a centrosome residing protein in breast carcinoma. J Immunother.
32:474–485. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang Y, Jin T, Dai X and Xu J:
Lentivirus-mediated knockdown of CEP55 suppresses cell
proliferation of breast cancer cells. Biosci Trends. 10:67–73.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kalimutho M, Sinha D, Jeffery J, Nones K,
Srihari S, Fernando WC, Duijf PH, Vennin C, Raninga P, Nanayakkara
D, et al: CEP55 is a determinant of cell fate during perturbed
mitosis in breast cancer. EMBO Mol Med. 10(pii): e85662018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen CH, Lai JM, Chou TY, Chen CY, Su LJ,
Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, et al: VEGFA
upregulates FLJ10540 and modulates migration and invasion of lung
cancer via PI3K/AKT pathway. PLoS One. 4:e50522009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu L, Mei Q, Zhao J, Dai Y and Fu Q:
Suppression of CEP55 reduces cell viability and induces apoptosis
in human lung cancer. Oncol Rep. 36:1939–1945. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang G, Liu M, Wang H, Yu S, Jiang Z, Sun
J, Han K, Shen J, Zhu M, Lin Z, et al: Centrosomal protein of 55
regulates glucose metabolism, proliferation and apoptosis of glioma
cells via the Akt/mTOR signaling pathway. J Cancer. 7:1431–1440.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhu H, Chen D, Tang J, Huang C, Lv S, Wang
D and Li G: Overexpression of centrosomal protein 55 regulates the
proliferation of glioma cell and mediates proliferation promoted by
EGFRvIII in glioblastoma U251 cells. Oncol Lett. 15:2700–2706.
2018.PubMed/NCBI
|
|
47
|
Li F, Jin D, Tang C and Gao D: CEP55
promotes cell proliferation and inhibits apoptosis via the
PI3K/Akt/p21 signaling pathway in human glioma U251 cells. Oncol
Lett. 15:4789–4796. 2018.PubMed/NCBI
|
|
48
|
Chen CH, Shiu LY, Su LJ, Huang CY, Huang
SC, Huang CC, Yin YF, Wang WS, Tsai HT, Fang FM, et al: FLJ10540 is
associated with tumor progression in nasopharyngeal carcinomas and
contributes to nasopharyngeal cell proliferation, and metastasis
via osteopontin/CD44 pathway. J Transl Med. 10:932012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen CH, Chien CY, Huang CC, Hwang CF,
Chuang HC, Fang FM, Huang HY, Chen CM, Liu HL and Huang CY:
Expression of FLJ10540 is correlated with aggressiveness of oral
cavity squamous cell carcinoma by stimulating cell migration and
invasion through increased FOXM1 and MMP-2 activity. Oncogene.
28:2723–2737. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xu L, Xia C, Sheng F, Sun Q, Xiong J and
Wang S: CEP55 promotes the proliferation and invasion of tumour
cells via the AKT signalling pathway in osteosarcoma.
Carcinogenesis. 39:623–631. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen CH, Chang AY, Li SH, Tsai HT, Shiu
LY, Su LJ, Wang WL, Chiu TJ, Luo SD, Huang TL and Chien CY:
Suppression of Aurora-A-FLJ10540 signaling axis prohibits the
malignant state of head and neck cancer. Mol Cancer. 14:832015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Weinberger P, Ponny SR, Xu H, Bai S,
Smallridge R, Copland J and Sharma A: Cell cycle M-phase genes are
highly upregulated in anaplastic thyroid carcinoma. Thyroid.
27:236–252. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Qi J, Liu G and Wang F: High levels of
centrosomal protein 55 expression is associated with poor clinical
prognosis in patients with cervical cancer. Oncol Lett.
15:9347–9352. 2018.PubMed/NCBI
|
|
54
|
Jia Y, Xiao Z, Gongsun X, Xin Z, Shang B,
Chen G, Wang Z and Jiang W: CEP55 promotes the proliferation,
migration and invasion of esophageal squamous cell carcinoma via
the PI3K/Akt pathway. Onco Targets Ther. 11:4221–4232. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jiang W, Wang Z and Jia Y: CEP55
overexpression predicts poor prognosis in patients with locally
advanced esophageal squamous cell carcinoma. Oncol Lett.
13:236–242. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Peng T, Zhou W, Guo F, Wu HS, Wang CY,
Wang L and Yang ZY: Centrosomal protein 55 activates NF-κB
signalling and promotes pancreatic cancer cells aggressiveness. Sci
Rep. 7:59252017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zheng H, Guo Z, Zheng X, Cheng W and Huang
X: MicroRNA-144-3p inhibits cell proliferation and induces cell
apoptosis in prostate cancer by targeting CEP55. Am J Transl Res.
10:2457–2468. 2018.PubMed/NCBI
|
|
58
|
Kulkarni P and Uversky VN: Cancer/testis
antigens: ‘Smart’ Biomarkers for diagnosis and prognosis of
prostate and other cancers. Int J Mol Sci. 18(pii): E7402017.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jones J, Otu H, Spentzos D, Kolia S, Inan
M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, et al: Gene
signatures of progression and metastasis in renal cell cancer. Clin
Cancer Res. 11:5730–5739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Luo T, Chen X, Zeng S, Guan B, Hu B, Meng
Y, Liu F, Wong T, Lu Y, Yun C, et al: Bioinformatic identification
of key genes and analysis of prognostic values in clear cell renal
cell carcinoma. Oncol Lett. 16:1747–1757. 2018.PubMed/NCBI
|
